Abstract:Tumor immunotherapies targeting PD-(L)1 exhibit anti-tumor efficacy in only 10-30% of patients with various cancers. Literature has demonstrated that a "hot tumor" which contains high T lymphocytes in the tumor microenvironment exhibits a better response to immunotherapies than a "cold tumor." This study aimed to investigate whether tumor-intrinsic IFNα and CXCL10 determine the recruitment and activation of CD8+ T cells to become "hot tumor." In this study, we found that CXCL10 overexpressed in a variety of tumors including lung, colon, and liver tumors with a correlation with PD-L1. High PD-L1 and CXCL10 are associated with better survival rates in tumor patients receiving immunotherapies. IFNs-downstream transcriptional factor IRF-1 and STAT1 were correlated with PD-L1 and CXCL10 expression. We demonstrated that IRF-1 and STAT1 were both bound with the promoters of PD-L1 and CXCL10, sharing the same signaling pathway and determining IFNs-mediated PD-L1 and CXCL10 expression. In addition, IFNα significantly increased activation marker IFNγ in PBMCs, promoting M1 type monocyte differentiation, CD4+ T, and CD8+ T cell activation. Particularly, we found that CD8+ T lymphocytes abundantly expressed CXCR3, a receptor of CXCL10, by flow cytometry, indicating that tumor-intrinsic CXCL10 potentially recruited CD8+ T in tumor microenvironment. To demonstrate the hypothesis, immunotherapy-sensitive CT26 and immunotherapy-resistant LL/2 were used and we found that CT26 cells exhibited higher IFNα, IFNγ, CXCL10, and PD-L1 levels compared to LL/2, leading to higher IFNγ expression in mouse splenocytes. Moreover, we found that CD8+ T cells were recruited by CXCL10 in vitro, whereas SCH546738, an inhibitor of CXCR3, inhibited T cell migration and splenocytes-mediated anti-tumor effect. We then confirmed that CT26-derived tumor was sensitive to αPD-L1 immunotherapy and LL/2-tumor was resistant, whereas αPD-L1 significantly increased T lymphocyte activation marker CD107a in CT26-derived BALB/c mice. In conclusion, this study revealed that CXCL10 expression is correlated with PD-L1 in tumors, sharing the same signaling pathway and associating with better immunotherapeutic efficacy. Further evidence in the syngeneic tumor models demonstrated that immunotherapy-sensitive CT26 intrinsically exhibited higher IFNα and CXCL10 compared to immunotherapy-resistant LL/2 to recruit and activate CD8+ T cells in the tumor microenvironment, exhibiting "hot tumor" characteristic of sensitizing αPD-L1 immunotherapies.

CD4 + T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors

CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment

The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer

Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity

cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity

Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses

CD4+ T cells help myeloid-mediated killing of immune-evasive tumors

Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response

Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity

Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4 + T cell response

Mechanisms of CD40-dependent cDC1 licensing beyond costimulation

IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

Finding the right help in the tumor microenvironment

Peripheral CD4 T cell resistance to type I interferon defines outcome of PD1 blockade therapy in human cancer

The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancer

CD4+ T cell help in cancer immunology and immunotherapy